Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Todellinen)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Quebec, Kanada, G1J 1Z4
- Hôpital de l'Enfant-Jésus
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R2H 2A6
- St. Boniface Hospital
-
Winnipeg, Manitoba, Kanada, R3A 1R9
- Winnipeg Health Sciences Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 3A7 and B3H 2Y9
- Capital Health - Queen Elizabeth II Health Sciences Centre
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8L 2X2
- Hamilton General Hospital
-
Hamilton, Ontario, Kanada, L8N 4A6
- St Joseph's Healthcare Hamilton
-
Ottawa, Ontario, Kanada, K1H 8L6
- Ottawa Hospital General Campus
-
Ottawa, Ontario, Kanada, K1Y 4E9
- Ottawa Hospital Civic Campus
-
Toronto, Ontario, Kanada, M5B 1W8
- St Michael's Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- ≥ 18 years of age
- Refractory hypotension documented within 36 hours prior to enrolment that requires institution and ongoing use of vasopressor agents (phenylephrine, norepinephrine, vasopressin, epinephrine, or dopamine > 5 mcg/kg/min) at the time of enrolment. Refractory hypotension is defined as a systolic blood pressure < 90 mmHG or a systolic blood pressure more than 30 mmHg below baseline, or a mean arterial pressure less than 65 mmHG and receipt of greater than or equal to 2 litres of intravenous fluid for the treatment of hypotension.
At least 1 other new organ dysfunction defined by the following:
- Creatinine ≥ 150 µmol/L, or ≥ 1.5x the upper limit of normal or the known baseline creatinine, or < 0.5 ml/kg or urine output for 2 hours(Patients on chronic hemodialysis or peritoneal dialysis must meet one of the following criteria)
- Need for invasive mechanical ventilation or a P/F ratio < 250
- Platelets < 100 x109/L, or a drop of 50 x109/L in the 3 days prior to enrollment
- Arterial pH < 7.30 or base deficit > 5 mmol/L in association with a lactate >/= to 3.0 mmol/L
Exclusion Criteria:
- Consent declined
- Clinically apparent other forms of shock including cardiogenic, obstructive (massive pulmonary embolism, cardiac tamponnade, tension pneumothorax), hemorrhagic, neurogenic, or anaphylactic
- Received vasopressor therapy for greater than 36 hours prior to enrollment
Have a significant risk of bleeding as evidenced by one of the following:
- Clinical: Surgery requiring general or spinal anesthesia within 24 hours prior to enrollment, or the potential need for such surgery in the next 24 hours; evidence of active bleeding; a history of severe head trauma requiring hospitalization; intracranial surgery, or stroke within 3 months before the study or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or mass lesions of the central nervous system; a history of congenital bleeding diatheses; gastrointestinal bleeding within 6 weeks before the study unless corrective surgery had been performed; trauma considered to increase the risk of bleeding; presence of an epidural catheter
- Laboratory: Platelet count < 30 x109/L, INR > 2.0, or baseline aPTT > 50 sec prior to enrollment.
- Have an indication for therapeutic anticoagulation (e.g. ACS, acute VTE, mechanical valve, etc)
- Intent of the most responsible physician to prescribe rhAPC
- Have had a known or suspected adverse reaction to UFH including HIT
- Are currently enrolled in related trial
- Known or suspected cirrhosis, or chronic ascites
- Use of any of the following medications or treatment regimens: unfractionated heparin to treat an active thrombotic event within 12 hours before the infusion enrollment; low-molecular-weight heparin at a higher dose than recommended for prophylactic use (as specified in the package insert) within 12 hours before the infusion; warfarin (if used within 7 days before study entry AND if the INR time exceeded the upper limit of the normal range for the institution); thrombolytic therapy within 3 days before the study, glycoprotein IIb/IIIa antagonists within 7 days before study entry; protein C or rhAPC within 24 hours before enrollment.
- Terminal illness with a life expectancy of less than 3 months
- Are pregnant
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kolminkertaistaa
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Unfractionated Heparin
|
Dose: 18 IU/kg/hr, continuous intravenous infusion.
Duration: up to 7 days or until ICU discharge or death
|
|
Active Comparator: Dalteparin
Standard of care
|
Dose 5000 IU, subcutaneous, daily
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Feasibility of enrollment - to enrol an average of 2 patients per site per month over the duration of the study
Aikaikkuna: 1 year
|
The primary measure of feasibility is the ability of participating sites to enroll an average of 2 patients per month.
|
1 year
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Feasibility(1) - Consent rate - will be considered adequate if 60% of eligible patients are enrolled in the HALO pilot
Aikaikkuna: 1 year
|
1 year
|
|
|
Safety - Rate of major and minor bleeding events
Aikaikkuna: Duration of ICU admission, or up to day +9
|
a.) Rates of major and minor bleeding will be adjudicated and will be considered in the context of monitored aPTTs: 1) in the context of aPTTs ≤95 seconds, the rate of major bleeding will be deemed acceptable if major bleeding occurs in ≤10% of patients; and 2) if >20% of patients require an initial (6 hour aPTT) dose reduction of the study drug due to an aPTT >95 seconds, this dose will be deemed infeasible as an initiation dose.
|
Duration of ICU admission, or up to day +9
|
|
Activation of coagulation - Thrombin-antithrombin (TAT) complexes
Aikaikkuna: Day 1, 2, 3, 5, 7, and 9 (or ICU discharge)
|
Day 1, 2, 3, 5, 7, and 9 (or ICU discharge)
|
|
|
Feasibility(2): Protocol Deviations - The investigators believe that an acceptable rate of protocol violations resulting in a non-scheduled dose reduction or interruption of the study drug to be less than 10% of all study drug dose adjustments
Aikaikkuna: Duration of study drug infusion or up to a maximum of 7 days
|
Duration of study drug infusion or up to a maximum of 7 days
|
|
|
Feasibility(3) - Time from randomization to initiation of study drug
Aikaikkuna: the outcome will be assessed during the first 24 hours of enrollment
|
The investigators will consider the time from randomization to study treatment initiation to be satisfactory if this interval is less than 4 hours.
|
the outcome will be assessed during the first 24 hours of enrollment
|
|
Activation of coagulation - Protein C concentration
Aikaikkuna: Day 1, 2, 3, 5, 7, and 9 (or ICU discharge)
|
Day 1, 2, 3, 5, 7, and 9 (or ICU discharge)
|
|
|
Activation of Coagulation - Quantitative d-dimer
Aikaikkuna: Days 1, 2, 3, 5, 7, and 9 (or ICU discharge)
|
Days 1, 2, 3, 5, 7, and 9 (or ICU discharge)
|
|
|
Markers of Inflammation (IL-6, IL-8, IL-10, and IL-17)
Aikaikkuna: Days 1, 2, 3, 5, 7, and 9 (or ICU discharge)
|
Days 1, 2, 3, 5, 7, and 9 (or ICU discharge)
|
|
|
ICU Mortality (Tertiary, descriptive outcome only)
Aikaikkuna: Will be assessed at the time of ICU discharge or death; expected average length of ICU admission is 5.7 days
|
Will be assessed at the time of ICU discharge or death; expected average length of ICU admission is 5.7 days
|
|
|
Hospital Mortality (Tertiary, descriptive outcome only)
Aikaikkuna: Will be assessed at the time of hospital discharge or death; expected average length of hospital admission is 14 days
|
Will be assessed at the time of hospital discharge or death; expected average length of hospital admission is 14 days
|
|
|
Change in MODS score (Tertiary, descriptive outcome only)
Aikaikkuna: Will be assessed daily during admission to the ICU; expected average length of ICU admission is 5.7 days
|
Will be assessed daily during admission to the ICU; expected average length of ICU admission is 5.7 days
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Päätutkija: Ryan Zarychanski, MD MSc, University of Manitoba
- Päätutkija: Dean Fergusson, PhD MHA, Ottawa Hospital Research Institute
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Ensisijainen valmistuminen
Opintojen valmistuminen (Todellinen)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Infektiot
- Systeeminen tulehdusvasteen oireyhtymä
- Tulehdus
- Sepsis
- Shokki, septinen
- Shokki
- Farmakologisen vaikutuksen molekyylimekanismit
- Fibrinolyyttiset aineet
- Fibriiniä moduloivat aineet
- Antikoagulantit
- Hepariini
- Kalsium hepariini
- Hepariini, pienimolekyylipainoinen
- Tinzapariini
- Daltepariini
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- HCA2011/001
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .